NYSE: LLYEli Lilly & Co Revenue
Eli Lilly & Co revenue was $45.04B for the trailing 12 months ending Dec 31, 2024, with 102.1% growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $13.5B, up 18.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, LLY annual revenue was $45.0B, with 32% growth year-over-year.
LLY past revenue growth
How has LLY's revenue growth performed historically?
Company
32%
Industry
14.44%
Market
20.87%
LLY's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
LLY's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
LLY's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
LLY revenue history
Current Revenue
$45.0B
Current Earnings
$10.6B
Current Profit Margin
23.5%
LLY's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance
Be the first to know when LLY announces revenue.
LLY Revenue History By Year
| LLY Yearly Revenue | LLY Revenue | LLY Change | LLY Revenue Growth |
|---|---|---|---|
| 2024-12-31 | $45.04B | $10.92B | +32.00% |
| 2023-12-31 | $34.12B | $5.58B | +19.56% |
| 2022-12-31 | $28.54B | $223.00M | +0.79% |
| 2021-12-31 | $28.32B | $3.78B | +15.40% |
| 2020-12-31 | $24.54B | $2.22B | +9.95% |
| 2019-12-31 | $22.32B | $826.20M | +3.84% |
| 2018-12-31 | $21.49B | $1.52B | +7.61% |
| 2017-12-31 | $19.97B | -$1.25B | -5.88% |
| 2016-12-31 | $21.22B | $1.26B | +6.33% |
| 2015-12-31 | $19.96B | $343.10M | +1.75% |
| 2014-12-31 | $19.62B | -$3.50B | -15.13% |
| 2013-12-31 | $23.11B | $509.70M | +2.25% |
| 2012-12-31 | $22.60B | -$1.68B | -6.93% |
| 2011-12-31 | $24.29B | $1.21B | +5.25% |
| 2010-12-31 | $23.08B | $1.24B | +5.68% |
| 2009-12-31 | $21.84B | $1.46B | +7.19% |
| 2008-12-31 | $20.37B | $1.74B | +9.33% |
| 2007-12-31 | $18.63B | $2.94B | +18.75% |
| 2006-12-31 | $15.69B | $1.05B | +7.14% |
| 2005-12-31 | $14.65B | $787.40M | +5.68% |
| 2004-12-31 | $13.86B | $1.28B | +10.14% |
| 2003-12-31 | $12.58B | $1.51B | +13.59% |
| 2002-12-31 | $11.08B | -$465.00M | -4.03% |
| 2001-12-31 | $11.54B | $680.30M | +6.26% |
| 2000-12-31 | $10.86B | $859.30M | +8.59% |
| 1999-12-31 | $10.00B | $766.10M | +8.29% |
| 1998-12-31 | $9.24B | $1.25B | +15.64% |
| 1997-12-31 | $7.99B | $989.40M | +14.14% |
| 1996-12-31 | $7.00B | $234.50M | +3.47% |
| 1995-12-31 | $6.76B | $1.05B | +18.42% |
| 1994-12-31 | $5.71B | $513.10M | +9.87% |
| 1993-12-31 | $5.20B | $235.40M | +4.74% |
| 1992-12-31 | $4.96B | -$762.60M | -13.32% |
| 1991-12-31 | $5.73B | N/A | N/A |
Eli Lilly & Co Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.